774 reports of this reaction
3.1% of all NEBIVOLOL reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for NEBIVOLOL, manufactured by ANI Pharmaceuticals, Inc.. There are 774 FDA adverse event reports linking NEBIVOLOL to DYSPNOEA. This represents approximately 3.1% of all 25,085 adverse event reports for this drug.
Patients taking NEBIVOLOL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among NEBIVOLOL users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for NEBIVOLOL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 774 FDA reports for NEBIVOLOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.1% of all adverse event reports for NEBIVOLOL, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking NEBIVOLOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.